Clinical Trials Logo

Filter by:
NCT ID: NCT04474483 Terminated - COVID-19 Clinical Trials

Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

COVID-19
Start date: November 6, 2020
Phase: Phase 2
Study type: Interventional

This study is a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in adult outpatients suspected to be afflicted with COVID-19.

NCT ID: NCT04474314 Terminated - Sickle Cell Disease Clinical Trials

A Study of IMR-687 in Subjects With Sickle Cell Disease

Start date: August 13, 2020
Phase: Phase 2
Study type: Interventional

A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

NCT ID: NCT04474210 Terminated - Renal Insufficiency Clinical Trials

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

Start date: August 19, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in adult participants with renal impairment compared with healthy participants with normal renal function.

NCT ID: NCT04473950 Terminated - Opioid-use Disorder Clinical Trials

The Effect of Chronic Pain on Delay Discounting in Methadone Patients

Start date: January 8, 2020
Phase: Phase 1
Study type: Interventional

The epidemic of opioid overdose deaths continues to rise, killing more persons in 2017 than HIV/AIDS at the height of that epidemic. Medication assisted treatment, including methadone and buprenorphine, is the standard of care for the treatment of opioid use disorder (OUD). However, chronic pain can reduce treatment efficacy during medication assisted treatment and is associated with illicit substance relapse, dropout, and subsequent overdose. Mechanisms by which chronic pain may influence the impulsive decision making (e.g., drug relapse) in persons with OUD have not been well characterized. A better understanding is needed of decision-making in this population. Two factors that can influence decisions to use drugs are impulsivity and acute opioid withdrawal. This proposal will test how chronic pain is associated with increases in impulsive decision making in OUD, whether impulsive decision making is greater when undergoing opioid withdrawal, and how catastrophizing may modify the association between withdrawal and impulsive decision making in patients with chronic pain and OUD. An ideal population for this developmental research project are methadone maintained patients, who show high treatment attendance rates and will therefore assure study efficiency and reliable completion.

NCT ID: NCT04473937 Terminated - Clinical trials for Hematologic Malignancy

Radiation Post-CAR T in Refractory Lymphoma

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).

NCT ID: NCT04473651 Terminated - Healthy Clinical Trials

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Start date: July 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.

NCT ID: NCT04472728 Terminated - Covid-19 Clinical Trials

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

COVA
Start date: August 26, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in patients with SARS-CoV-2 pneumonia. Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide preliminary data on the activity, safety and tolerability of BIO101 in the target population. Part 2 is a phase 3 pivotal randomized study to provide further evidence of safety and efficacy of BIO101 after 28 days of double-blind dosing. BIO101 is the investigational new drug that activates the Mas receptor (MasR) through the protective arm of the Renin Angiotensin System (RAS).

NCT ID: NCT04472494 Terminated - COVID-19 Clinical Trials

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

NCT ID: NCT04471415 Terminated - Clinical trials for Advanced Solid Tumor

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Start date: August 31, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous injection as a single agent and in combination with atezolizumab in patients with advanced solid tumors and to assess preliminary safety and efficacy of which route of administration (intravenous or subcutaneous) will be selected for further development for the one expansion of patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations.

NCT ID: NCT04470622 Terminated - COVID-19 Clinical Trials

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

Start date: July 20, 2020
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.